EPIDEMIOLOGY AND GENETICS OF ALZHEIMER´S DISEASE

Slides:



Advertisements
Similar presentations
Epidemiology of Dementia
Advertisements

OCCUPATION, APOLIPOPROTEIN E EPSILON2 ALLELE AND PARKINSON'S DISEASE RISK IN ISRAEL Peretz C 1, Bar-Shira A 2,4, Orr-Urtreger A 2,4, Giladi N 3,5,Peretz.
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Dementia and Alzheimer Disease: Current Realities and Future Possibilities Peter V. Rabins, MD, MPH Johns Hopkins School of Medicine.
Etiopathogenesis of Alzheimer's disease
Genetics of longevity 1.Heritability Exceptional longevity (90+) a. appears to be a real category b. what is the basis? -reduced incidence.
Epidemiological study of mild cognitive impairment and pilot evaluation of methods of early dementia detection in Chinese community Yueqin Huang MD MPH.
The real dementia challenge Age UK November 2013.
PRACTICE PARAMETER: RISK OF DRIVING AND ALZHEIMER ’ S DISEASE (AN EVIDENCE-BASED REVIEW) Richard M. Dubinsky, MD; Anthony C. Stein, PhD; and Kelly Lyons,
Alzheimer’s Disease By Juan Escobar Per: 4. Alzheimer’s Disease  A common form of dementia of unknown cause, usually beginning in late middle age, characterized.
Risk Factors in a Group of Puerto Rican Patients with Alzheimer’s Dementia Heriberto A. Acosta M.D.¹ Irving Vega Ph.D.² Clara Camacho M.S.² ¹Judith Irizarry.
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
“Does African ancestry protect against dementia? A population-based case-control study in an admixed Cuban population?. ” Juan J. Llibre Rodriguez, Beatriz.
Health Economics and Technology Assessment Research Centre Katalin Érsek 1, Krisztián Kárpáti 1, Tibor Kovács 2, László Gulácsi.
Epidemiology of Dementia in Canada: Information from the Canadian Study of Health and Aging.
MILD COGNITIVE IMPAIRMENT IN PATIENTS WITH CAROTID DISEASE Irena Martinic Popovic 1, M.D, Arijana Lovrencic-Huzjan 1, M.D, Ph. D, Ana-Maria Simundic 2,
Spatial Statistics for Cancer Surveillance Martin Kulldorff Harvard Medical School and Harvard Pilgrim Health Care.
Glucose Levels and Risk of Dementia Presented by - Anas Kabaha, MD Sheba medical center Sheba medical center August 8,2013.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
CHAPTER 24: Converging Issues in Heart Disease, Stroke, and Alzheimer’s Disease in Women.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
The best of both worlds Pharma R&D IT - Informatics Rudi Verbeeck Guided analytics in the hands of the SME.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Alzheimer’s. What is it? Type of dementia Progressive brain disease Effects memory, thinking and behavior problems.
Cognitive Impairment Disorders. Assessing Brain Damage  Mental status examination  Information about current behavior and thought including orientation.
Are There Sex Differences in sociodemographic background and cognitive Functions Among Patients With dementia,a comparative study among an Egyptian sample.
1 A follow up study of mild cognitive impairment in Beijing ----finding from 10/66 study Zhaorui Liu, Chuanjun Zhuo, Yueqin Huang, Shuran Li, Institute.
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
ALZHEIMER’S DISEASE Sania Munir Medical Biotechnology (BIOT 412)
The Effect of ApoE Genotype, Plasmalogen Biosynthesis, and Reverse Cholesterol Transport Biomarkers on Cognition and Odds of Alzheimer’s Disease in Elderly.
CL Ropp 1, SL Tyas 1, KP Riley 2, KS SantaCruz 3 1 University of Waterloo, 2 University of Kentucky, 3 University of Minnesota March 29, 2011 The Impact.
Prognostic factors in systemic lupus erithematosus Author: Nicoleta Roman Cooauthor: Anicua-Ionela Morar Coordinator: Lecturer Dr. Monica Copotoiu U.M.F.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
Polymorphisms in the CRP and C1 Q genes and schizophrenia in Armenian population: A pilot study Zakharyan R 1,2, Khoyetsyan A 1, Chavushyan A 1, Arakelyan.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Epidemiology of Alzheimer’s Disease
Ethnicity and Cardiovascular Disease Africans Americans.
Association of functional polymorphisms of Bax and Bcl2 genes with schizophrenia Kristina Pirumya, PhD, Laboratory of Human Genomics and Immunomics Institute.
FUNCTIONAL VARIANT OF THE ANXA11 GENE: TRUE MARKER OF PROTECTION AND CANDIDATE DISEASE MODIFIER IN SARCOIDOSIS Stahelova A 1, Mrazek F 1, Kriegova E 1,
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Unit 12: Abnormal Psychology Psychological Disorder Presentations Mrs. Marsh.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
GENETIC MARKERS OF CORONARY ARTERY DISEASE RISK GALYA ATANASOVA MD, PhD DOMINIC JAMES.
Alzheimer’s Disease (AD)
Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
Chapter 14 Neurocognitive Disorders
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
1 Predicting Dementia From Vascular Conditions Among Tennessee Medicare Elderly Baqar A. Husaini, PhD Professor & Director, Center for Health Research.
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
Dementia Jaqueline Raetz, M.D..
PLASMA HOMOCYSTEINE LEVELS AS A PREDICTOR
Changing demographics and the impact on dementia
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
Dementia Jaqueline Raetz, M.D..
Apolipoprotein E gene polymorphisms (rs and rs7412) in the healthy Bosnian population as a complement the European data. Grażyna Adler 1, Amina.
Imaging AD Progression Amyloid Imaging Agents.
Modifying Disease Course in Alzheimer's Disease
Li-Yu Tang1, Ta-Fu Chen1,2, Ming-Jang Chiu1,2*
Does Multilingualism Protect Against Alzheimer’s Disease
DPUK cohort: Generation Scotland
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

EPIDEMIOLOGY AND GENETICS OF ALZHEIMER´S DISEASE Jana Povova, Omar Sery, Hana Tomaskova, Petr Ambroz, Anna Pohlidalova, Vladimir Janout Department of Epidemiology and Public Health, Ostrava, Czech Republic Department of Biochemistry, Brno, Czech Republic

INTRODUCTION It is generally accepted that Alzheimer´s disease (AD) is the most frequent form of dementia. Etiology of AD is still unknown and there are three hypotheses, what risk factors are responsible for development of the disease: - vascular risk factors - genetic risk factors - behavioral risk factors

EPIDEMIOLOGY From different reasons there are no exact data about the incidence and prevalence of AD - no compulsory notification - difficult to distinguish between different forms of dementia - no exact diagnostic test There are mostly only estimates of real incidence or prevalence … in the Czech Republic 120 000 cases of AD notified

STUDY Since 2010 we have been performing an epidemiological study to assess the importance of selected risk factors from vascular and genetic fields. The aim of the study is to recruit 800 cases of AD and 800 controls. In this paper we report some preliminary results from analyses of 394 cases and 287 controls.

DIAGNOSTIC CRITERIA CASES - MMSE < 24 - slow development of cognitive impairment - other forms of dementia excluded (CT exam.) CONTROLS - MMSE > 28 - same gender and age (± 5 years)

EPIDEMIOLOGICAL DATA Recruitment: 394 Cases 130 Controls Gender: 79 % females 76 % females Age (average) 79 73 96,7 % of cases with late onset (after 65 years) Education: in group of cases 49 % elementary,72 % lower than high school in group of controls 36 % high school Clinical course: in 85 % slow

SELECTED VASCULAR RISK FACTORS cases controls OR 95% CI p-value % CVD 52 % 43 %   1,44 0,94-2,19 0,089 Diabetes 29 % 38 %  0,67 0,44-1,02 0,062 Hypertension 69 %   79 %   0,57 0,36-0,92 0,022 Stroke 15 % 22 %   0,63 0,38-1,04 0,069 Head Injury 4 %   6 %   0,69 0,29-1,64 0,403

GENETICS We start with focusing on genes: - Apolipoprotein E (ApoE) - Angiotensin Converting Enzyme (ACE) Gene for ApoE is found on chromosome 19q13.2 and has 3 major alleles 2,3,4. It has 6 genotypes depending on combination of these three alleles. The allele 4 is the only confirmed genetic factor contributing to both early and late onset of AD.

GENETICS ACE gene is located on the chromosome 17q23 and has 2 major alleles I and D. It has 3 genotypes depending on combination of these two alleles. It was reported that the ID and II genotypes are associated with the risk of AD (DD genotype is considered as neuroprotective).

Apolipoprotein E (ApoE) ApoE4 allele significantly increase the risk of AD. (OR 2,52; 95% CI 1,832-3,482) In both files the genotype E3/E3 was most frequent (cases 47 % and controls 60 %) The frequency of genotype E4/E4 was in cases  3 %, in controls  0,3 % only.

Frequency of apolipoprotein alleles % patients (n=373) 5,23 70,64 24,13 controls (n=286) 10,49 78,32 11,19 OR 0,47 0,66 2,52 (95% CI) X (1,832-3,482)

Frequency of apolipoprotein E genotypes (%) E2/E2 E2/E3 E3/E3 E2/E4 E3/E4 E4/E4 patients (n=373) 0,27 6,97 47,45 2,95 39,41 controls (n=286) 0,70 17,48 59,80 2,09 19,58 0,35 OR X 1,41 2,67 8,66 (95% CI) 0,51 – 3,88 1,86 – 3,82 1,11 – 67,48 p-value 0,62 ˂0,0000 0,01

Genotypes ACE Allele I increases risk of AD (OR 1,08; 95% CI 0,87 – 1,34) but so far difference is not significant. In both files the genotype ID was most frequent – cases 49 % and controls 57 %. Genotype II was in cases in 22 % and in controls in 17 % (marginal significant difference – OR 1,43 95% CI 0,97-2,12)   

Frequency of I, D alleles (%) patients (n=384) 47,14 52,86 controls (n=287) 45,12 54,88 OR 1,08 0,92 (95% Cl) 0,87 – 1,34 0,74 – 1,14 p-value 0,472

Frequency of genotypes (%) II ID DD patients (n=384) 22,39 49,48 28,13 controls (n=287) 16,72 56,79 26,49 OR 1,43 0,75 1,09 (95% CI) 0,97-2,12 0,54-1,01 0,77-1,53

Conclusions – vascular risk factors In patients with AD were CVD more often in their history compare to controls but the difference was not significant. Diabetes, stroke and hypertension were inversely related to AD what is contrary to some published results. In case of hypertension the inversal difference was statisticaly significant. The same finding was published by some other researchers.

Conclusions – genetic risk factors Relationship between ApoE4 allele and AD was confirmed in presented paper with high statistical significance, what make it possible diagnostic marker for AD. In ACE gene was only marginal reliance of alelle I presence and higher risk of AD development.

THANK YOU FOR YOUR ATTENTION